Cannabis Strategic Ventures (NUGS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cannabis Strategic Ventures (NUGS) trades at $0.001 with AI Score 42/100 (Grade C). Cannabis Strategic Ventures cultivates marijuana products and partners within the cannabis and ancillary sectors in the United States. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for NUGS: NUGS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NUGS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NUGS: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Cannabis Strategic Ventures (NUGS) Healthcare & Pipeline Overview
Cannabis Strategic Ventures, operating in the U.S. cannabis market, focuses on cultivation and partnerships within the cannabis and ancillary sectors. The company's negative profit margin and OTC market listing highlight the risks and challenges it faces in a competitive industry.
What Is the Investment Thesis for NUGS?
Cannabis Strategic Ventures presents a speculative investment opportunity within the cannabis sector, characterized by high risk and potential reward. The company's negative profit margin of -87.3% and listing on the OTC market indicate significant financial challenges. The company's success hinges on its ability to achieve profitability through efficient cultivation, strategic partnerships, and expansion into new markets. Growth catalysts include potential changes in cannabis regulations and increased consumer demand. However, investors should be aware of the risks associated with investing in a small, unprofitable company in a volatile industry. The company's beta of -31.42 suggests an inverse correlation with the market, which could be a factor during market downturns.
Based on FMP financials and quantitative analysis
NUGS Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher volatility.
- Negative P/E ratio of -0.04 reflects the company's lack of profitability.
- Gross margin of 9.4% suggests challenges in cost management and pricing strategy.
- Profit margin of -87.3% highlights significant operational inefficiencies and financial strain.
- Beta of -31.42 indicates a negative correlation with the market, which may offer some downside protection but also limits upside potential.
Who Are NUGS's Competitors?
NUGS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NUGS's Key Strengths?
Cultivation expertise.
- Strategic partnerships.
- Focus on the cannabis market.
- Location in California.
What Are NUGS's Weaknesses?
Negative profitability.
- Limited financial resources.
- Small market capitalization.
- OTC market listing.
What Could Drive NUGS Stock Higher?
NUGS catalyst: Potential changes in cannabis regulations at the state or federal level could create new opportunities for Cannabis Strategic Ventures.
- Increasing consumer demand for cannabis products could drive revenue growth.
- Strategic partnerships with established cannabis companies could accelerate the company's expansion.
- Development and launch of new cannabis-infused products could attract new customers.
- Cost-cutting measures and operational improvements could improve profitability.
What Are the Key Risks for NUGS?
Financial-distress signal — its Altman Z-Score of -11.89 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger, more established cannabis companies.
- Regulatory uncertainty and changes in cannabis laws could negatively impact the company's operations.
- Fluctuations in cannabis prices could affect revenue and profitability.
- Limited access to capital could hinder the company's growth plans.
- Negative profitability and financial strain could lead to bankruptcy.
What Are the Growth Opportunities for NUGS?
- Expansion into new markets: As more states legalize cannabis, Cannabis Strategic Ventures has the opportunity to expand its cultivation and distribution operations into these new markets. This expansion could significantly increase the company's revenue and market share, provided it can secure the necessary licenses and permits. The timeline for this growth opportunity depends on the pace of legalization in different states, but it could begin to materialize within the next 1-3 years.
- Development of new cannabis-infused products: Cannabis Strategic Ventures can capitalize on the growing demand for cannabis-infused products by developing and launching new products in categories such as edibles, beverages, and topicals. These products can command higher margins and attract a wider range of consumers. The timeline for this growth opportunity is relatively short, with new products potentially launching within the next 6-12 months.
- Strategic partnerships with established cannabis companies: Partnering with larger, more established cannabis companies can provide Cannabis Strategic Ventures with access to capital, distribution networks, and expertise. These partnerships can accelerate the company's growth and improve its competitive position. The timeline for securing these partnerships is uncertain, but it could happen within the next 1-2 years.
- Focus on high-quality cultivation practices: By focusing on cultivating high-quality cannabis strains, Cannabis Strategic Ventures can differentiate itself from competitors and command premium prices. This requires investment in advanced cultivation technologies and skilled personnel. The timeline for this growth opportunity is ongoing, as the company continuously strives to improve its cultivation practices.
- Exploration of international markets: As cannabis legalization spreads globally, Cannabis Strategic Ventures can explore opportunities to expand its operations into international markets. This could provide access to new customers and revenue streams. The timeline for this growth opportunity is longer-term, potentially 3-5 years, as the company needs to navigate the regulatory and logistical challenges of operating in foreign countries.
What Are NUGS's Competitive Advantages?
- Proprietary cultivation techniques (if any).
- Strategic partnerships within the cannabis industry.
- Early mover advantage in specific markets (if any).
What Does NUGS Do?
Cannabis Strategic Ventures, based in Los Angeles, California, engages in the cultivation of marijuana products within the United States. The company operates in the cannabis and ancillary sectors, focusing on incubating, developing, and partnering with other businesses. Since its inception, Cannabis Strategic Ventures has aimed to capitalize on the growing cannabis market by establishing cultivation operations and forming strategic alliances. The company's activities include cultivating various strains of cannabis, developing cannabis-infused products, and exploring opportunities in related sectors such as cannabis technology and retail. Cannabis Strategic Ventures seeks to differentiate itself through quality cultivation practices and strategic partnerships, although it faces competition from larger, more established players in the cannabis industry. The company's geographic focus is primarily within the United States, targeting states with legalized cannabis markets. Its success depends on navigating the complex regulatory landscape and effectively executing its growth strategy in a rapidly evolving market.
What Products and Services Does NUGS Offer?
- Cultivates marijuana products in the United States.
- Incubates cannabis-related businesses.
- Develops cannabis-related products and services.
- Partners with companies in the cannabis sector.
- Operates in the cannabis and ancillary sectors.
- Aims to capitalize on the growing cannabis market.
How Does NUGS Make Money?
- Cultivation and sale of marijuana products.
- Incubation and development of cannabis-related businesses.
- Strategic partnerships within the cannabis industry.
What Industry Does NUGS Operate In?
Cannabis Strategic Ventures operates within the rapidly evolving cannabis industry, which is characterized by increasing legalization, growing consumer demand, and intense competition. However, the industry faces regulatory hurdles, including varying state laws and federal prohibition. Cannabis Strategic Ventures competes with other cannabis cultivators and producers, including AOLS, CBGI, FIORF, HCANF, and HSMD, some of whom have greater access to capital and established distribution networks. The company's success depends on its ability to navigate the complex regulatory landscape and differentiate itself in a crowded market.
Who Are NUGS's Key Customers?
- Consumers in states with legalized cannabis markets.
- Businesses in the cannabis and ancillary sectors.
- Partners seeking to expand their presence in the cannabis industry.
Financial Health
Cannabis Strategic Ventures's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.89 places it in the distress zone, a signal of elevated financial risk.
NUGS Valuation & Market Position
Relative to its peer group, NUGS's quantitative score of 42/100 is below the peer average of 62/100.
Key Financial Metrics
Return on equity for Cannabis Strategic Ventures stands at 102.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -77.0%, showing how much profit it generates from its asset base. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Cannabis Strategic Ventures operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Simon Yu. NUGS has traded publicly since 2009.
NUGS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Cultivation expertise.
- Strategic partnerships.
- Focus on the cannabis market.
- Location in California.
Bear Case
- Negative profitability.
- Limited financial resources.
- Small market capitalization.
- OTC market listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
NUGS Latest News
No recent news available for NUGS.
NUGS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NUGS.
Price Targets
Wall Street price target analysis for NUGS.
NUGS MoonshotScore
What does this score mean?
The MoonshotScore rates NUGS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Simon Yu
CEO
Simon Yu is the CEO of Cannabis Strategic Ventures. Information regarding his detailed career history, education, and previous roles is not available in the provided data. As CEO, he is responsible for overseeing the company's strategic direction, operations, and financial performance. He manages approximately 30 employees.
Track Record: Information regarding Simon Yu's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. His tenure at Cannabis Strategic Ventures is unknown.
NUGS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cannabis Strategic Ventures may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulation and transparency compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low liquidity and high price volatility.
- Higher risk of fraud or manipulation.
- Lack of regulatory oversight.
- Going concern risk due to negative profitability.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capital structure and debt levels.
- Understand the risks associated with investing in the cannabis industry.
- Consult with a financial advisor before investing.
- Confirm share structure and outstanding shares.
- Cultivation operations in the United States.
- Partnerships within the cannabis sector.
- Existence of a CEO and management team.
- Company has been in operation for several years.
- Publicly traded status, even on the OTC market.
Cannabis Strategic Ventures Healthcare Stock: Key Questions Answered
What does the AI Score mean for NUGS?
NUGS holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Cannabis Strategic Ventures cultivates marijuana products and partners within the cannabis and ancillary sectors in the United States. The company faces challenges with profitability and operates …
What does Cannabis Strategic Ventures do?
Cannabis Strategic Ventures cultivates marijuana products in the United States and partners with other businesses in the cannabis and ancillary sectors. The company focuses on incubating and developing cannabis-related products and services, aiming to capitalize on the growing demand for cannabis in legalized markets.
What do analysts say about NUGS stock?
There is currently no available analyst coverage or consensus on Cannabis Strategic Ventures (NUGS) stock. Given its OTC listing and small market capitalization, the company is unlikely to be actively followed by major research firms. Investors should conduct their own thorough due diligence and consider the risks associated with investing in a micro-cap company in a volatile industry.
What are the main risks for NUGS?
Cannabis Strategic Ventures faces significant risks, including intense competition in the cannabis industry, regulatory uncertainty, and fluctuations in cannabis prices. The company's negative profitability and limited financial resources pose a substantial threat to its long-term viability. As an OTC-listed company, NUGS is subject to less stringent regulatory oversight and faces higher risks of fraud or manipulation. Investors should carefully consider these risks before investing in NUGS.
What revenue streams does Cannabis Strategic Ventures have in healthcare?
Cannabis Strategic Ventures generates revenue primarily through the cultivation and sale of marijuana products in states where cannabis is legalized for medical or recreational use. The company's revenue streams are directly tied to the demand for cannabis products in these markets. The specific breakdown of revenue by product line (e.g., flower, concentrates, edibles) is not available in the provided data.
How does Cannabis Strategic Ventures plan to achieve profitability?
Cannabis Strategic Ventures' path to profitability hinges on several factors. The company needs to improve its gross margin, which currently stands at 9.4%, by optimizing cultivation practices and reducing production costs. Expanding into new markets and developing new cannabis-infused products could also drive revenue growth and improve profitability.
What are the key factors to evaluate for NUGS?
Cannabis Strategic Ventures (NUGS) holds an AI score of 42/100 (low). Cannabis Strategic Ventures presents a speculative investment opportunity within the cannabis sector, characterized by high risk and potential reward. Not financial advice.
How frequently does NUGS data refresh on this page?
NUGS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NUGS's recent stock price performance?
Cannabis Strategic Ventures (NUGS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Cultivation expertise. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available for Cannabis Strategic Ventures.
- OTC market listing indicates higher risk and lower transparency.
- Lack of analyst coverage limits independent assessment of the company.